The Venture Codex Logo

The Venture Codex

Overview

Investment firm focused on life sciences and healthcare.

Founded

2012

Deals ยท 12mo

7

Stage focus

Series A
Series B
Series C

Geographic focus

United States

Sector focus

Biotechnology
Financial Services
Life Science

Investment portfolio

181rounds
NAMEDATESIZE
Multiply Labs
Oct 2026Participated
$75 MSeries B
Flare Therapeutics
Jun 2026Participated
$85 MSeries C
Serapha Bio
Jun 2026Participated
$138 MSeries A
City Therapeutics
Jun 2026Participated
$100 MSeries B
Beacon Biosignals
Apr 2026Participated
$11 MSeries B
Apella Technology
Jan 2026Participated
$80 MSeries B
Beacon Biosignals
Nov 2025Participated
$86 MSeries B
Octave
Sep 2025Participated
$51 MSeries C
Treeline Biosciences
Sep 2025Participated
$200 MSeries A
Leyden Labs
Jan 2025Participated
$70 MOther Equity
nChroma Bio
Dec 2024Participated
$75 MOther Equity
Idrx
Aug 2024Participated
$120 MSeries B
Multiply Labs
Oct 2026Participated
$75 MSeries B
Flare Therapeutics
Jun 2026Participated
$85 MSeries C
Serapha Bio
Jun 2026Participated
$138 MSeries A
City Therapeutics
Jun 2026Participated
$100 MSeries B
Beacon Biosignals
Apr 2026Participated
$11 MSeries B
Apella Technology
Jan 2026Participated
$80 MSeries B
Beacon Biosignals
Nov 2025Participated
$86 MSeries B
Octave
Sep 2025Participated
$51 MSeries C
Treeline Biosciences
Sep 2025Participated
$200 MSeries A
Leyden Labs
Jan 2025Participated
$70 MOther Equity
nChroma Bio
Dec 2024Participated
$75 MOther Equity
Idrx
Aug 2024Participated
$120 MSeries B
181
Items
...
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Casdin Capital: 181 funding rounds are recorded in the selected participation categories.All available history.
Casdin Capital: 181 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Seed03
Series A1133
Series B953
Series C+643
Other Equity418
Debt01

Monthly Deal Activity

Casdin Capital: 181 deals are recorded across 155 months.All available history.
Casdin Capital: 181 deals are recorded across 155 months. All available history
MonthDeals
Dec '131
Jan '142
Feb '140
Mar '140
Apr '140
May '140
Jun '140
Jul '140
Aug '140
Sep '140
Oct '141
Nov '141
Dec '140
Jan '150
Feb '150
Mar '150
Apr '153
May '151
Jun '151
Jul '150
Aug '151
Sep '150
Oct '151
Nov '150
Dec '150
Jan '162
Feb '160
Mar '160
Apr '160
May '160
Jun '160
Jul '160
Aug '160
Sep '160
Oct '160
Nov '160
Dec '160
Jan '170
Feb '170
Mar '171
Apr '170
May '170
Jun '170
Jul '170
Aug '170
Sep '171
Oct '170
Nov '172
Dec '172
Jan '180
Feb '180
Mar '180
Apr '184
May '182
Jun '180
Jul '181
Aug '180
Sep '182
Oct '181
Nov '180
Dec '181
Jan '190
Feb '191
Mar '190
Apr '192
May '191
Jun '191
Jul '191
Aug '190
Sep '191
Oct '192
Nov '190
Dec '191
Jan '202
Feb '201
Mar '203
Apr '201
May '201
Jun '204
Jul '204
Aug '204
Sep '204
Oct '204
Nov '201
Dec '206
Jan '214
Feb '214
Mar '219
Apr '214
May '215
Jun '214
Jul '212
Aug '215
Sep '214
Oct '214
Nov '215
Dec '215
Jan '227
Feb '222
Mar '226
Apr '220
May '223
Jun '220
Jul '221
Aug '221
Sep '221
Oct '220
Nov '221
Dec '220
Jan '232
Feb '230
Mar '232
Apr '232
May '230
Jun '230
Jul '232
Aug '231
Sep '231
Oct '230
Nov '230
Dec '230
Jan '241
Feb '241
Mar '240
Apr '241
May '241
Jun '240
Jul '242
Aug '241
Sep '240
Oct '240
Nov '240
Dec '241
Jan '251
Feb '250
Mar '250
Apr '250
May '250
Jun '250
Jul '250
Aug '250
Sep '252
Oct '250
Nov '251
Dec '250
Jan '261
Feb '260
Mar '260
Apr '261
May '260
Jun '263
Jul '260
Aug '260
Sep '260
Oct '261

Sector Breakdown

Casdin Capital: Health & Life Sciences is the largest displayed sector by deal count (174 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Casdin Capital: Health & Life Sciences is the largest displayed sector by deal count (174 deals). All available history
SectorDeals
Health & Life Sciences174
Space & Frontier Tech20
AI & Machine Learning17
Manufacturing12
Hardware & Robotics9
Data, Analytics & IT9
Enterprise Software8
Consumer & Lifestyle4
Clean Energy & Sustainability3
Developer Tools2
Networks, Cloud & Communication2
Marketing & Advertising2
Fintech1

Deal Size Distribution

Casdin Capital: 181 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Casdin Capital: 181 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M2
$5M-$10M5
$10M-$25M22
$25M-$50M22
$50M-$100M60
$100M-$250M60
$250M-$500M10
$500M-$1B0
$1B+0

Deals By Geography

Casdin Capital: United States has the largest recorded deal count among the displayed regions (161 deals).All available history.

Top 5 of 5 regions; European countries are grouped as Europe.

Casdin Capital: United States has the largest recorded deal count among the displayed regions (161 deals). All available history
RegionDeals
United States161
Europe15
China2
Canada2
South Korea1
Casdin Capital: 20 co-investors are shown, with Google Ventures sharing 42 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Investment Strategy

Casdin Capital: Led accounts for 17% and participating for 83% of round participation.All available history.
Casdin Capital: Led accounts for 17% and participating for 83% of round participation. All available history
CategoryDeals (count)Share (%)
Led3017%
Participating15183%
Casdin Capital: Single-lead accounts for 53% and co-led for 47% of lead dynamics.All available history.
Casdin Capital: Single-lead accounts for 53% and co-led for 47% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead1653%
Co-led1447%

Team

Eli Casdin

managing partner

John Graziano

Platform Investor Relations & Syndication Lead

Suzanne Angell

Director of Research